Maravai LifeSciences Holdings, Inc. (MRVI) vs Urogen Pharma (URGN)
- Maravai LifeSciences Holdings, Inc. MRVI 6.79 −3.96%
- Urogen Pharma URGN 34.56 −5.60%
Maravai LifeSciences Holdings, Inc. and Urogen Pharma are both Biotechnology companies. Maravai LifeSciences Holdings, Inc. and Urogen Pharma are of similar size ($1.8B and $1.8B). Urogen Pharma grew revenue faster over the last twelve months: 100.3% against −5.03%. Maravai LifeSciences Holdings, Inc. has the higher net margin (−37.1% vs −51.7%) and the lower return on invested capital (−15.8% vs 0.00%). Across the 17 metrics below, Maravai LifeSciences Holdings, Inc. leads on 9 and Urogen Pharma on 8.
Valuation
Profitability
| Metric | MRVI | URGN | Biotechnology median |
|---|---|---|---|
| Gross margin | 34.89% | 90.85% | 65.16% |
| Operating margin | (56.08%) | (35.32%) | 0.00% |
| Net margin | (37.07%) | (51.73%) | 0.00% |
| Free cash flow margin | (17.17%) | (84.32%) | 0.00% |
| Return on equity | (18.79%) | 86.49% | (56.36%) |
| Return on assets | (10.31%) | (42.33%) | (48.04%) |
| Return on invested capital | (15.83%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack